Key result
Attenuating oxidative stress, inflammation, and fibrosis offers a promising strategy to disrupt cardiorenal syndrome.
Why the study?
Cardiorenal syndrome involves complex bidirectional heart-kidney interactions, but there remains a major unmet need for therapies that specifically target their shared pathophysiological pathways.
Targeting the interconnected pathways of oxidative stress, inflammation, and fibrosis offers a promising integrated therapeutic strategy for managing the bidirectional organ dysfunction in cardiorenal syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for multi-pathway targeting in cardiorenal syndrome; prospective trials needed before clinical adoption.
Cardiorenal syndrome (CRS) is characterized by a complex, bidirectional interaction between cardiac and renal dysfunction, posing a significant challenge in clinical practice. Although these two organ dysfunctions share common pathophysiological pathways, there remains a major unmet need for therapies that specifically target these shared mechanisms. Oxidative stress, chronic low-grade inflammation, and progressive tissue fibrosis are pivotal, interconnected drivers involved in the progression of both chronic heart failure and chronic kidney disease, constituting a critical pathological triad in CRS. This review aims to systematically elucidate the interplay among reactive oxygen species (ROS), immune cell infiltration, proinflammatory cytokine signaling, and fibrotic pathway activation in the pathogenesis of CRS. We also provide a comprehensive overview of the current landscape of novel pharmacological candidates that target key nodes in the oxidative stress–inflammation–fibrosis axis, including small molecules, biologics, and repurposed drugs. By integrating preclinical evidence with clinical trial data, this review highlights the therapeutic potential of concurrently attenuating oxidative stress, inflammation, and fibrosis to disrupt the vicious cycle of CRS and ultimately improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Cardiorenal syndrome. Integrated therapeutic strategies targeting oxidative stress, inflammation, and fibrosis was evaluated. Concurrent attenuation of oxidative stress, inflammation, and fibrosis represents a promising integrated therapeutic strategy to disrupt the vicious cycle of cardiorenal syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: